GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer
The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.
You may also be interested in...
ESMO: Lynparza, Zejula Continue Rivalry With Long-Term Ovarian Maintenance Data
AstraZeneca/Merck’s Lynparza showed an OS benefit in first-line maintenance of ovarian cancer, but while data for Zejula were less mature, the GSK drug targets a broader population.
GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter
Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.
ESMO Preview: Five Key Oncology Battlegrounds To Watch
GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.